司库奇尤单抗治疗银屑病导致严重湿疹一例  

Severe eczema in one patient with secukinumab for plaque psoriasis: a case report

作　　者：王娜[1] 暴芳芳[1] 崔晓晨 周盛基[1] 施仲香[1] WANG Na;BAO Fangfang;CUI Xiaochen;ZHOU Shengji;SHI Zhongxiang(Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of Dermatology and Venereology,Shandong First Medical University,Jinan 250022,China)

机构地区：[1]山东第一医科大学附属皮肤病医院(山东省皮肤病医院),山东省皮肤病性病防治研究所,济南250022

出　　处：《中国麻风皮肤病杂志》2022年第6期393-395,共3页China Journal of Leprosy and Skin Diseases

基　　金：国家自然基金青年科学基金项目(编号:81903230);山东省医药卫生科技发展计划项目(编号:202004120262)。

摘　　要：Secukinumab是第一个完全人源化的抗白介素17A单克隆抗体,已成功治疗中重度斑块状银屑病。这些新的靶向药物越来越普遍,但长期副作用尚不完全清楚.目前国际上已有患者应用司库奇尤单抗后出现类似汗疱疹和痤疮样皮损皮疹的报道。本文报道司库奇尤单抗治疗银屑病患者后发生严重红皮病,并出现手足汗疱疹样改变1例。Secukinumab was the first fully human anti-interleukin-17 a monoclonal antibody and successfully treated moderate-severe psoriasis. These new targeted medications are becoming more popular, but long-term side effects are not entirely clear. Dyshidrotic eczema and pompholyx are rare variants of dermatitis characterized by vesicles or bullae on the palms, soles and sides of the fingers. At present, the cases of patients with similar skin rashes after using secukinumab in the world have been reported. Herein, we present one case of erythroderma, accompany with dyshidrotic eczema in a patient with secukinumab for psoriasis.

关 键 词：司库奇尤单抗 斑块状银屑病 汗疱疹 

分 类 号：R969[医药卫生—药理学]